Daily use of the rotigotine transdermal patch appears to provide continued safety and efficacy in patients with early Parkinson's disease, according to interim data from the open-label extension phase of a Phase III multicenter, randomised, double-blind, placebo-controlled study.
Patients were entered into the trial's open label phase if they had completed the double-blind treatment protocol. In total, 177 patients were randomised to rotigotine and 96 patients to placebo for six months. The study drug was initiated at a dose of 2 mg every 24 hour (10 cm2) for three weeks to a maximum dose of 6 mg/ 24 hour (30 cm2). After one year of open-label treatment patients could receive up to 16 mg/24 hour (80 cm2).